Edwards Lifesciences Co. (NYSE:EW) Given Average Rating of “Hold” by Brokerages

Shares of Edwards Lifesciences Co. (NYSE:EW) have received a consensus rating of “Hold” from the twenty-six brokerages that are presently covering the stock, Marketbeat reports. Fifteen analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $75.67.

A number of brokerages have commented on EW. Evercore ISI decreased their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. Jefferies Financial Group downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $85.00 to $70.00 in a research note on Wednesday, September 18th. The Goldman Sachs Group decreased their target price on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research note on Friday, July 26th. JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Finally, StockNews.com downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th.

Edwards Lifesciences Stock Down 1.1 %

Shares of Edwards Lifesciences stock opened at $68.63 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The firm has a market cap of $41.36 billion, a P/E ratio of 29.58, a P/E/G ratio of 3.00 and a beta of 1.13. Edwards Lifesciences has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The business has a 50-day moving average price of $68.07 and a 200 day moving average price of $77.92.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the firm posted $0.59 earnings per share. Edwards Lifesciences’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, sell-side analysts forecast that Edwards Lifesciences will post 2.61 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,262,521.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,262,521.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,250 shares of company stock valued at $1,099,238. Corporate insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the first quarter valued at $28,000. First Community Trust NA purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $29,000. Webster Bank N. A. purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $39,000. Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at $40,000. Finally, Versant Capital Management Inc lifted its holdings in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 326 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.